Science & Evidence

Ibogaine Research Database

86 peer-reviewed studies indexed from PubMed. Plain-language summaries where available.

All Studies (86)Opioid Addiction (15)Heroin Addiction (15)PTSD (15)Depression (15)Alcohol Addiction (15)Cocaine Addiction (15)Anxiety (13)Methamphetamine Addiction (12)Traumatic Brain Injury (2)

Studies on Depression(8)

← Back to Depression

Exploring the Use of Ibogaine in Opioid Recovery: Insights from Lived Experience.

Walker, Deering, Unger· Journal of psychoactive drugs· 2026· PMID: 42171381

Opioid dependence is a public health concern in New Zealand, with limited treatment options beyond opioid substitution therapy (OST). Ibogaine, a psychoactive alkaloid with reported anti-withdrawal and anti-craving effects for opioid dependence, is legally available by prescripti...

Deciphering Ibogaine's Matrix Pharmacology: Multiple Transporter Modulation at Serotonin Synapses.

Hwu, Havel, Westergaard· Journal of the American Chemical Society· 2026· PMID: 41452009

Ibogaine is the main psychoactive alkaloid produced by the iboga tree (Tabernanthe iboga) that has a unique therapeutic potential across multiple indications, including opioid dependence, substance use disorders, depression, anxiety, posttraumatic stress disorder (PTSD), and trau...

Psychedelics, entactogens and psychoplastogens for depression and related disorders.

Hoyer· British journal of pharmacology· 2026· PMID: 40518133

Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N-dimethyltryptamine, ayahuasca; non-hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplas...

Changing your mind: neuroplastic mechanisms underlying the therapeutic effect of psychedelics in depression, PTSD, and addiction.

Palhas, Corne, Mongeau· Progress in neuro-psychopharmacology & biological psychiatry· 2025· PMID: 41130352

After years of restrictions due to concerns about their potentially harmful effects, research on psychedelics has entered a new era. Increasing attention has been directed toward their immense therapeutic potential, particularly for psychiatric disorders. Pre-clinical and clinica...

Trauma-Informed Care in Psychedelic Therapy Research: A Qualitative Literature Review of Evidence-Based Psychotherapy Interventions in PTSD and Psychedelic Therapy Across Conditions.

Modlin, Creed, Sarang· Neuropsychiatric disease and treatment· 2024· PMID: 38268571

Post-traumatic stress disorder (PTSD) is associated with significant patient burden. While pharmacotherapies and evidence-based psychotherapy interventions (EBPI) are effective, studies consistently highlight inadequate outcomes and high treatment dropout. Psychedelic therapy (PT...

Psychedelic Therapy: A Primer for Primary Care Clinicians-Ibogaine.

Cherian, Shinozuka, Tabaac· American journal of therapeutics· 2024· PMID: 38518270

Ibogaine is a plant-derived alkaloid that has been used for thousands of years in rites of passage and spiritual ceremonies in West-Central Africa. In the West, it has primarily been used and studied for its anti-addictive properties and more recently for other neuropsychiatric i...

Registered clinical studies investigating psychedelic drugs for psychiatric disorders.

Siegel, Meshkat, Benitah· Journal of psychiatric research· 2021· PMID: 34048997

Psychedelics are a hallucinogenic class of psychoactive drugs with the primary effect of activating non-ordinary states of consciousness. Due to the positive preliminary findings of these drugs in the treatment of psychiatric disorders, the number of registered clinical studies h...

DARK Classics in Chemical Neuroscience: Ibogaine.

Wasko, Witt-Enderby, Surratt· ACS chemical neuroscience· 2018· PMID: 30216039

The West African iboga plant has been used for centuries by the Bwiti and Mbiri tribes to induce hallucinations during religious ceremonies. Ibogaine, the principal alkaloid responsible for iboga's psychedelic properties, was isolated and sold as an antidepressant in France for d...